UK Industry Rebates Could Make NICE Cost-Effectiveness Assessments Unnecessary
Executive Summary
Roche has praised the flexibility of the UK’s Cancer Drugs Fund, but says NICE cost-effectiveness analysis would be unnecessary if industry rebates fed into a UK drugs budget.